KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue (2016 - 2025)

Supernus Pharmaceuticals has reported Revenue over the past 15 years, most recently at $211.6 million for Q4 2025.

  • Quarterly Revenue rose 21.48% to $211.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $719.0 million through Dec 2025, up 8.63% year-over-year, with the annual reading at $719.0 million for FY2025, 8.63% up from the prior year.
  • Revenue was $211.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $192.1 million in the prior quarter.
  • Over five years, Revenue peaked at $211.6 million in Q4 2025 and troughed at $130.9 million in Q1 2021.
  • The 5-year median for Revenue is $161.7 million (2021), against an average of $161.8 million.
  • Year-over-year, Revenue soared 37.86% in 2021 and then decreased 20.28% in 2023.
  • A 5-year view of Revenue shows it stood at $159.0 million in 2021, then grew by 5.2% to $167.3 million in 2022, then decreased by 1.8% to $164.3 million in 2023, then grew by 5.99% to $174.2 million in 2024, then rose by 21.48% to $211.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Revenue are $211.6 million (Q4 2025), $192.1 million (Q3 2025), and $165.5 million (Q2 2025).